Highlights

  • Healius (ASX:HLS) reported FY26 underlying Earnings Before Interest and Tax (EBIT) of A$30.2 million, up 76.6% year on year.
  • The company recorded a A$332.0 million pre-tax non-cash Goodwill impairment, resulting in a statutory net loss after tax.
  • Pathology EBITDA increased 6.4% to A$247.9 million with Margin expansion during FY26.
  • Healius is exploring a potential sale of Agilex Biolabs while progressing FY27 recovery initiatives.

Healius (ASX:HLS) reported improved underlying operating performance in FY26 while managing restructuring outcomes, Impairment charges and a cautious FY27 outlook. The company has progressed cost reduction initiatives and margin improvements, with future performance dependent on continued operational recovery.

What happened

Healius released its FY26 results on 19 August 2026, reporting Revenue from continuing operations of A$1,373.2 million, up 2.1% year on year.

Pathology revenue increased 1.8% to A$1,329.6 million, while Agilex Biolabs revenue increased 14.1% to A$43.6 million.

Underlying operating performance improved, with Earnings Before Interest, Tax, Depreciation and Amortisation (EBITDA) increasing to A$258.6 million from A$239.3 million in FY25. Underlying EBIT increased to A$30.2 million from A$17.1 million.

However, a A$332.0 million pre-tax non-cash goodwill impairment resulted in a reported EBIT loss of A$328.9 million and a net loss after tax of A$415.6 million.

Healius did not declare an interim, special or final Dividend for FY26.

The company also confirmed it has appointed UBS Securities Australia to explore strategic Options for Agilex Biolabs following unsolicited approaches from potential acquirers.

The numbers investors need to know

Pathology EBITDA increased 6.4% to A$247.9 million, with divisional margin improving by 80 basis points to 18.6%.

Agilex Biolabs reported EBITDA of A$10.7 million, up 67.2%, and EBIT of A$6.4 million, up 137.0%, with an EBIT margin of 14.7%.

Healius ended FY26 with net Debt of A$32.8 million compared with net cash of A$57.2 million in the prior year. Net Tangible Asset backing moved to a Liability position of A$(0.07) per share from positive A$0.01.

Capital expenditure during FY26 was A$42.8 million. Cash movements were affected by several one-off items, including an approximately A$20 million Australian Taxation Office settlement, a A$22 million Lumus Imaging true-up and digital Investment expenditure.

The company’s T27 transformation programme delivered A$24.4 million in annualised corporate cost savings and reduced regional laboratory headcount by 24.3% compared with FY25.

Genomics revenue increased 16.9%, with growth also reported in business-to-business Clinical Trials and veterinary pathology.

Business outlook and key considerations

Healius is focused on improving profitability through cost savings, pathology margin expansion and operational efficiency initiatives.

For FY27, management expects EBIT of approximately A$39.7 million, while incorporating around A$15 million of additional Fair Work Commission-related wage costs.

The company expects cost growth to remain contained at approximately 3.5% including these wage impacts. Management has also extended its expectation for achieving mid-to-high single-digit EBIT margins to approximately December 2028.

Key areas to monitor include pathology margin performance, Cash Flow generation, Agilex Biolabs strategic options and progress towards longer-term margin targets.

Bull case

Healius has demonstrated operational improvement through FY26, with underlying EBIT increasing significantly and pathology margins expanding.

The company has completed major restructuring activities, including A$24.4 million in annualised corporate cost savings, while digital transformation initiatives have progressed.

Management expects positive cash flow during FY27 as one-off expenditure reduces and Capital Expenditure requirements moderate. A potential Agilex Biolabs transaction could also provide additional Balance Sheet flexibility.

Bear case and risks

The A$332.0 million goodwill impairment highlights challenges around the carrying value of acquired Assets and the pace of recovery.

Healius returned to a net debt position after previously holding net cash, while no dividend was declared for FY26. Labour cost increases remain a key factor, with Fair Work Commission-related costs expected to affect FY27.

Additional risks include Medicare funding settings, competitive pressures within pathology services, execution of transformation initiatives and uncertainty around the Agilex Biolabs process.

What comes next

Healius will provide further updates on the Agilex Biolabs strategic review process ahead of its annual general meeting.

Key areas to monitor include delivery against FY27 EBIT guidance, progress towards positive cash flow, pathology margin trends, wage cost impacts and future Medicare funding developments.

Conclusion

Healius (ASX:HLS) delivered improved underlying earnings performance in FY26 while facing significant accounting and operational challenges. The company increased pathology profitability, reduced costs through its transformation programme and progressed strategic options for Agilex Biolabs.

The next phase will depend on converting operational improvements into sustainable earnings growth, managing higher labour costs and achieving longer-term margin objectives.